PI3K / Akt / mTOR pathway | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

16,210 results for “PI3K / Akt / mTOR pathway”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

13 participants · First posted Dec 16, 2009

ITMCTR2200005640

To explore the mechanism of Yishen Tongluo formula affecting the apoptosis of varicocele vein endothelial cells in varicocele infertility patients based on PI3K/AKT/mTOR pathway

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

120 participants · First posted Jul 9, 2018

Tongyangxiao Lotion for Postoperative Wound Healing After Anal Fistula Surgery

115 participants · First posted May 1, 2026

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

14 participants · First posted Sep 23, 2021

Not yet recruiting

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

70 participants · First posted Feb 4, 2026

Pharmacodynamic Study of BKM120 in Breast Cancer

20 participants · First posted Jan 20, 2012

Not yet recruiting

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

270 participants · First posted Feb 3, 2021

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

203 participants · First posted Jul 20, 2023

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

205 participants · First posted Aug 7, 2025

Page 1 of 876